REG - MaxCyte, Inc. MaxCyte, Inc. - MXCR - Total Voting Rights

MaxCyteAnnouncement

04/03/2025 15:45

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20250304:nRSD3328Za&default-theme=true

RNS Number : 3328Z  MaxCyte, Inc.  04 March 2025

MaxCyte, Inc.

 

("MaxCyte" or the "Company")

 

Total Voting Rights

 

ROCKVILLE, MD, 4 March 2025: MaxCyte Inc., (Nasdaq: MXCT; LSE: MXCT), a
leading, cell-engineering focused company providing enabling platform
technologies to advance the discovery, development and commercialization of
next-generation cell-based therapeutics, announces that pursuant to its block
admission facility, since 31 January 2025 it has issued 112,986 of common
stock, $0.01 par, of the Company ("Common Stock") in satisfaction of the
exercise of share options and/or vesting of restricted stock units.

Total voting rights

As at 28 February 2025, the total issued stock capital of the Company
following the recent issue of the new Common Stock is 105,958,833 shares of
Common Stock. Shareholders in the Company may use this figure as the
denominator for the calculations by which they will determine if they are
required to notify their interest in, or a change to their interest in, the
stock capital of the Company.

For further information, please contact:

 

    MaxCyte Contacts:

    US IR Adviser                                 +1 415-937-5400

    Gilmartin Group                               ir@maxcyte.com

    David Deuchler, CFA

    Nominated Adviser and Joint Corporate Broker

    Panmure Liberum                               +44 (0)20 7886 2500

    Emma Earl / Freddy Crossley

    Corporate Broking

    Rupert Dearden

    UK IR Adviser                                 +44 (0)203 709 5700

    ICR Healthcare                                maxcyte@icrhealthcare.com

    Mary-Jane Elliott

    Chris Welsh

About MaxCyte

At MaxCyte, we pursue cell engineering excellence to maximize the potential of
cells to improve patients' lives. We have spent more than 25 years honing our
expertise by building best-in-class platforms, perfecting the art of the
transfection workflow, and venturing beyond today's processes to innovate
tomorrow's solutions. Our ExPERT™ platform, which is based on our Flow
Electroporation® technology, has been designed to support the rapidly
expanding cell therapy market and can be utilized across the continuum of the
high-growth cell therapy sector, from discovery and development through
commercialization of next-generation, cell-based medicines. The ExPERT family
of products includes: four instruments, the ATx™, STx™, GTx™ and VLx
™; a portfolio of proprietary related processing assemblies or disposables;
and software protocols, all supported by a robust worldwide intellectual
property portfolio. By providing our partners with the right technology
platform, as well as scientific, technical and regulatory support, we aim to
guide them on their journey to transform human health. Learn more
at maxcyte.com
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=XLnMCc6YRZ3sNJujVZPY5nNMNTwyNxy2Qvs6RjWLmTF5e5gVLosc0I2kz2EPKRTmLq9RvBrxQssmPlUBPBeZlNFmcLAPl4WQruB2bgbCWsEPqcO5iqbxSvzmqrVDIquqV5v1b9Ufg14xPZ6SYv0IPV3brN7B5nNp_d-_zieJt01O852ZPk1x1OVN0cJI1ymQFJzeTi4iUEl_WpvGsaKZ3WNYr9LURZsrbhh_Z3gGbdqg5l29lshvFUs9qhGjeqc0pNHeHVjRrdw0i3TdNgtjJVob7KHH9HjL6cIfnefUG-zx7LQW3A0-AVWdjZ-zgSAk6e9-XSdHVx9il0PCNthfffKbYMfdzPM34TVsOPcT7P-pWyg_V7ZNx8dIOrlwQmNC___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplNzA0NWQ4MTM2NGE5NzVjZjM2NWQ2NzdjYTA4YWMyODo2OjAyNmE6ZGU1NDYzNmFlZDgwMTNhYzcwOWI0Nzk5OGE4MjM1MDMyYzRmNGM5NTcwNmRhMTIxMTAzNjFkOTBlMDkyMGRhZTpwOlQ6Rg)
 and follow us on X
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=uP47ND5f35pjgmUBFXgnnGAaWS6WlwkCG2Tp6c2M7Y2UTuxYC9N0pqGVlUNVwDaEVVLRz-AF-0Z7XmIznMFCEAkAlcs2IpBtLFhXg8drev4HUSfVpELHFQbtUGYRhFP89I4j6Q8kycJc8H54ICMU8IyhkLldVJh0BKqAcbOepVLthN0nK_ny3PGuJprK1GYcIoyZcfnYNQPAJThoeRMzYkapPe4tpCrLwti5McAoXwFZskyfgTZuvayuYu2DIQbSOaL3HhigwLdtT-K7bxQmEpTgU1kL3E8D6hqXMih1AGjQGKe5FUaESGLZl_bY7m2tUutKlrVvoJDH4QgPJ2qyjUBtaMqRHncbO2U3MDoaD1GYeUgCs6gAdcGeXPix6vf9___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplNzA0NWQ4MTM2NGE5NzVjZjM2NWQ2NzdjYTA4YWMyODo2OjJhYzA6ZWU2NDdkYjkzNTgwYjAxZjdmZDlkMzA0OTQ5MGEzZjg1NGY3ZmVhYTlmOTEzZDMyY2U4NmQ1NDMyOTM3NTkzYjpwOlQ6Rg)
 and LinkedIn
(https://protect.checkpoint.com/v2/___https:/www.globenewswire.com/Tracker?data=O6G2b_IbwGcbjm5wJP2pDGagPkz8XSoasVPSyqJvCERAlJwEhXU4fsgMNDSsALr-Mdi6jF9uAE5txTME5sd_QTOyOGDfU1stmMZKM_QDa-en31_LMXKxLHnbMJEqpNlv8Xi93vlwmBJL6UwaJDJCXKxDU98kQewSQY9ir1qXN5fKTLhTGuffkFfrkT9kw2PM7eqkgRsSVNjPdAy9QzzEN1o_OcnUjtRB9LGRWQ6svSHlzsd23uyJkMKwIm-YSI8Kmb27MMiGJuxBWdVEYh_ABdwojyPcGZZz27-LVDEqUpOCyfW-u_0dhh47m98F7RfWkMZ_MFXL5vf7LSWVWQClNOcC2v5nAB1X3OgoVi5xZLOVmOehwfC0lju3EtdEIxy0HyyrU6nI2zayMHPnAcq5Aw==___.YzJ1OmdpbG1hcnRpbmdyb3VwOmM6bzplNzA0NWQ4MTM2NGE5NzVjZjM2NWQ2NzdjYTA4YWMyODo2OjYyY2E6NGE4MzU1NTRjZWY1ZjQzNWRmYWI1NDI3YjM2YTNmMDkxMjAxOGQ2MzFiMjFkYmJmNmM3NTc1M2U1ZTZmYjBkYjpwOlQ6Rg)
.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TVRPKQBNPBKDFNK